VPTDF - Ventripoint Extends Patent Portfolio with Foundational U.S. Provisional Patent Filing of Heart Motion Tracking Technology
(TheNewswire)
Toronto, Ontario - The Newswire -April 19, 2021 - Ventripoint Diagnostics Ltd.(" Ventripoint " or the " Company "), (TSXV:VPT ) ( OTC:VPTDF) has filed a U.S.provisional patent application for its novel cardiac measurementapproach.
This new measurement technique provides cardiologistswith additional and more precise information about the function of theheart through motion tracking. This invention is as an extension ofthe Company’s existing artificial intelligence (AI) platform, whichprovides accurate and reliable volumetric measurements for all fourchambers of the heart.
“Since Ventripoint’s VMS+3.0 system produces amathematical model of the entire heart throughout the cardiac cycle,we are able to create novel measurements to characterize the functionof the whole heart. This is now becoming even more important withthe myriad of effects of COVID-19 on the heart,” stated Dr. GeorgeAdams, Executive-Chairman of Ventripoint.
This new technology tracks the movement of heart andvalves through the entire heartbeat and not just at the full and emptypoints in the cardiac cycle. This dynamic information can help ininitial diagnosis and assessing the effectiveness of treatments, aswell as the timing of interventions thereby improving clinicaloutcomes.
Cardiovascular diseases continue to be the number 1cause of death worldwide. Constantly advancing the tools available toclinicians for treating and diagnosing patients is key for the futureof healthcare.
For more information on the Ventripoint products,please refer to the Ventripoint website: www.ventripoint.com .
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all of Ventripoint's products that guide our futuredevelopments. In addition, VMS+ is versatile and can be used with allultrasound systems from any vendor supported by regulatory marketapprovals in the U.S., Europe and Canada.
For further information, pleasecontact:
Mr. Jonathan Robinson
Email :JRobinson@oakhillfinancial.ca
Phone: (416)669-1001????????????????? ????????????
Or
Mr. Anthony Allocca
Email: aa@sdthc.com
Phone: 858-456-7300
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.
Copyright (c) 2021 TheNewswire - All rights reserved.